ellume Logo

Overview

Ellume was founded during the 2009 H1N1 pandemic by Dr Sean Parsons. Working as a physician in an emergency department, he faced a lack of fast, accurate diagnostic tests that were essential in reducing transmission and enabling early treatment.

Through its technical innovations, Ellume has developed, manufactured, and commercialized the next generation of rapid, highly accurate and affordable digital diagnostic products.

ellume manufacturing facility

Our Story

Despite advances in modern medicine, infectious diseases continue to pose a significant threat to humanity. Ellume was founded to address these problems through innovative approaches to diagnosis and treatment accessibility.

During the 2009 swine flu pandemic I was working as a physician in a busy emergency department. Scores of patients were presenting with symptoms of influenza. Laboratory tests took several days to return results and the small range of rapid influenza tests available lacked accuracy and reliability. Inappropriate prescribing of antivirals and antibiotics was unavoidable, as was non-prescribing for influenza infected patients. It was then that I realised there was a clear need for a faster, simpler and more accurate way to diagnose influenza and other infectious diseases.

The technology Ellume developed to meet this need consists of several layers of innovation. Investment in the core science has been significant and has resulted in multiple patent families. Around this core science we’ve wrapped simple, intuitive user interfaces with smart-device connectivity to create unique products.

Our technology has enabled us to create a digital diagnostic platform used across our entire product range. By integrating our high-performance diagnostic technology with smart devices and software, we are delivering additional value and are achieving better health outcomes. As we proceed, we’ll be looking to build on these strengths of digital, connected diagnostics and bring high-impact products to commercialization.

Our vision is a world where people return to health as soon as possible. Our purpose is to create digital diagnostic solutions that link people to optimal therapy.
Meet our Team
Board Directors
Executive Team
Board Directors

Board Directors

Our dedicated team is comprised of executives with proven experience in leading healthcare, diagnostics, finance, law, fast-moving consumer goods and technology organisations. We share a mutual passion for innovating healthcare and challenging conventional thinking to achieve our goals.
Dr Sean Parsons
Dr Sean Parsons
Founder & Chief Executive Officer
Sean is the Founder, CEO and Managing Director of Ellume, a digital diagnostics company that develops, manufactures and commercializes high-performance, connected products for health professionals and consumers.
Read Bio
Geoff Pearce
Geoff Pearce
Chairman
Geoff is a Non-Executive Director of McPherson’s Ltd and a founding investor and Non-Executive Director of Cann Ltd. These companies’ activities include CMO in the pharmaceutical industry, brand owner and management in health beauty and wellness and early stage development of medical cannabis cultivation.
Read Bio
Dr Sean Parsons
Dr Sean Parsons
Founder & Chief Executive Officer
Sean is the Founder, CEO and Managing Director of Ellume, a digital diagnostics company that develops, manufactures and commercializes high-performance, connected products for health professionals and consumers.
Read Bio
Geoff Pearce
Geoff Pearce
Chairman
Geoff is a Non-Executive Director of McPherson’s Ltd and a founding investor and Non-Executive Director of Cann Ltd. These companies’ activities include CMO in the pharmaceutical industry, brand owner and management in health beauty and wellness and early stage development of medical cannabis cultivation.
Read Bio
Dr Sean Parsons
Dr Sean Parsons
Founder & Chief Executive Officer
Sean is the Founder, CEO and Managing Director of Ellume, a digital diagnostics company that develops, manufactures and commercializes high-performance, connected products for health professionals and consumers.
Read Bio
Geoff Pearce
Geoff Pearce
Chairman
Geoff is a Non-Executive Director of McPherson’s Ltd and a founding investor and Non-Executive Director of Cann Ltd. These companies’ activities include CMO in the pharmaceutical industry, brand owner and management in health beauty and wellness and early stage development of medical cannabis cultivation.
Read Bio
Paul Darrouzet
Paul Darrouzet
Non-Executive Director
Read Bio
Gary Hewett
Gary Hewett
Non-Executive Director
Read Bio
Jonathan Dooley
Jonathan Dooley
Non-Executive Director
Read Bio
Geoff Smith
Geoff Smith
Chief Financial Officer (Interim)
Read Bio
Mark Anning
Mark Anning
General Counsel and Company Secretary
Read Bio
Mirja Moenninghoff
Mirja Moenninghoff
Chief Marketing Officer
Read Bio
Dan Mallon
Dan Mallon
Senior Vice President, Business Development
Read Bio
Myriam Battistutta
Myriam Battistutta
Global Head Quality & Regulatory Affairs
Read Bio

A culture of excellence

We are proud of the recognition we have received for our ongoing contributions to the development of innovative emerging technology for the benefit of humanity.

IEEE Advancing Technology for Humanity award
Popular Science Best of What's New award
Time 100 Best Inventions of 2021
Fierce 15 award
2nd Annual BioBuzz awards
Financial Review Boss Most Innovative Companies
Australia's Biotechnology Organisation award
Brisbane Young Entrepreneur award
Good Design Award Best in Class
Lord Mayor's Business Awards winner 2021
AmCham Alliance award
IEEE Advancing Technology for Humanity award
Popular Science Best of What's New award
Time 100 Best Inventions of 2021
Fierce 15 award
2nd Annual BioBuzz awards
Financial Review Boss Most Innovative Companies
Australia's Biotechnology Organisation award
Brisbane Young Entrepreneur award
Good Design Award Best in Class
Lord Mayor's Business Awards winner 2021
AmCham Alliance award
IEEE Advancing Technology for Humanity award
Popular Science Best of What's New award
Time 100 Best Inventions of 2021
Fierce 15 award
2nd Annual BioBuzz awards
Financial Review Boss Most Innovative Companies
Australia's Biotechnology Organisation award
Brisbane Young Entrepreneur award
Good Design Award Best in Class
Lord Mayor's Business Awards winner 2021
AmCham Alliance award
*The Ellume COVID-19 Home Test has not been FDA cleared or approved; but has been authorized by the FDA under an emergency use authorization. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetics Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. **The ellume·lab COVID Antigen Test has not been FDA cleared or approved, but has been authorized by the FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. ***QIAreach™ Anti-SARS-CoV-2 Antigen Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
We use cookies
Ellume Limited values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Others are optional: performance cookies show us how you use our website and features; functional cookies remember your preferences; and advertising cookies help us share relevant content. Cookies Policy.